PerkinElmer SARS-CoV-2 RT-PCR Assay Receives CE Mark for Saliva and Sample Pooling to Test Symptomatic and Asymptomatic Individuals
20.11.2020 10:00:00 EET | Business Wire | Press release
PerkinElmer, Inc. announced today that its PerkinElmer® SARS-CoV-2 Real-time RT-PCR Assay received CE-IVD marking for the use of saliva as specimen type and the option to pool up to five specimens collected from individuals suspected of COVID-19 or asymptomatic individuals.
SARS-CoV-2 testing using saliva is less invasive, reduces the risk of exposure to healthcare workers involved in sample collection and need for frequent replacement of personal protective equipment.
Labs in countries accepting CE mark now have the option to accept saliva specimens and implement sample pooling using the PerkinElmer SARS-CoV-2 Real-time RT-PCR Assay. Sample pooling using saliva specimens is a critical advancement made possible by PerkinElmer’s chemistry and stringent manufacturing systems. The PerkinElmer SARS-CoV-2 Real-time RT-PCR Assay is built on the most sensitive SARS-CoV-2 test with the lowest limitation of detection in the market, according to the FDA’s reference panel comparative data.
The assay originally obtained its CE mark in the spring of 2020.
“To strike the right balance between keeping the world economy moving while ensuring safe practices, governments and private organizations are working tirelessly to increase the number of times individuals are tested for COVID-19,” said Masoud Toloue, Ph.D., Vice President & General Manager, Diagnostics, PerkinElmer. “We expect our newly released saliva-based collection and asymptomatic test solution will play a large role in this effort.”
PerkinElmer continues to work on the frontlines of improving COVID-19 testing. The Company’s comprehensive SARS-CoV-2 offerings span high throughput RNA extraction, RT-PCR, automation, ELISA, chemiluminescence, time-resolved fluorescence and lateral flow based serology testing.
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119006186/en/
Contact information
Chet Murray
(781) 663-5728
chet.murray@perkinelmer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 21:18:00 EEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 20:35:00 EEST | Press release
Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. “The integration with Somnoware is a welcomed enhancement that broadens access to the Onera hPSG® solution,” states Ruben de Francisco, Founder and CEO of Onera Health. “Many sleep centers are customers of both Onera and Somn
Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 19:18:00 EEST | Press release
The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies and societies worldwide, the Community is designed to convert global perspectives and practical expe
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 19:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease driven by orexin deficiency, and while excessive daytime sleepiness and cataplexy are the most recognized symptoms, many people experience additional bothersome symptoms such as cognitive difficulties and disrupted nighttime sleep," said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-861-3001) Phase 3 stu
Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders15.6.2026 18:30:00 EEST | Press release
Boomi, the data activation company for AI, today announced it has been recognized as aPioneer in the Gartner® Emerging Market Quadrant for No-Code Agent Builders (NCAB). Gartner defines the NCABs market as SaaS-delivered products that offer an integrated design and runtime environment to build, publish and manage AI-powered agents without using coding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615413216/en/ Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders Boomi sees this recognition as a reflection of the company's rapid evolution from an integration and automation powerhouse to a full-scale agentic infrastructure platform, expanding Boomi’s role in the emerging agentic AI market. A New Chapter in Enterprise Agentic AI According to Gartner, vendors recognized as a Pioneer in this quadrant have established themselves in enterprises for integration and automation workloads
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom